UCB Reports 25% Revenue Growth in First Half of 2025
Belgian pharmaceutical group UCB announced a 25% increase in turnover to 3.49 billion euros for the first half of 2025, prompting the company to raise its financial projections, expecting at least 7 billion euros in revenue by 2025, according to a press release.
Net sales reached 3.32 billion euros, marking a 26% rise. Additionally, the company’s underlying profitability, measured by adjusted EBITDA, surged to 1.03 billion euros, reflecting a remarkable 58% increase.
CEO Jean-Christophe Tellier commented, “Our performance in the first half of 2025 showcases our ambition and execution capabilities for robust and sustainable growth over the next decade and beyond.” He emphasized the firm’s commitment to helping individuals with severe diseases lead the best lives possible, free from disease-related challenges.
Operating from its headquarters in Brussels, UCB is renowned for producing various medications, including Bimzelx, Rystiggo, Zilbrysq, Evenity, and Fintepla.
Staff at UCB’s Biomanufacturing Operations Center in Braine l’Alleud, April 2024 © BELGA PHOTO LAURIE DIEFFEMBACQ
, reports 24brussels.
